gastric epithelial tumor
Conditions
Interventions
Vonoprazan 20 mg administration for 21 days
Sponsors
Oita Red Cross Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Planned to undergo endoscopic resection (ESD or EMR) for early gastric cancer and gastric adenomas discovered after successful eradication. 2. For early gastric cancer, absolute adaptive lesion and adaptive enlarged lesion are treated as the target lesion according to the gastric cancer treatment guideline. 3. ECOG-performance Status is 0 or 1. 4. For participation in the study, informed consent was obtained.
Exclusion criteria
Exclusion criteria: Patients within 6 months from the day of eradication 2. Patients with antacid drugs before the first observation (within 7 days) 3. Patients with lesions with ulcers and bleeding which are difficult to observe the surface of the lesion 4. Patients with severe underlying disease 5. Patients with a history of gastrectomy 6. Patients who have complicated mental illness or psychiatric symptoms and seem to be difficult to participate in the study. 7. Other patients who are deemed inappropriate for the trial responsible physician or the test sharing doctor to conduct this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in tumor WOS expression (positive proportion) before and after Vonoprazan administration. | — |
Secondary
| Measure | Time frame |
|---|---|
| Relationship between WOS expression and fasting gastric juice pH. Relationship between WOS expression and tumor histopathology (adenoma VS differentiation dominant VS undifferentiated dominant) | — |
Countries
Japan
Contacts
Public ContactTetsuya Ueo
Oita Red Cross Hospital Gastroenterology
Outcome results
None listed